NCT07485569

Brief Summary

This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible and safe to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments can help control the growth of the patient tumors or stop them from getting worse.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_1

Timeline
15mo left

Started Jun 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Jun 2026Sep 2027

First Submitted

Initial submission to the registry

July 18, 2023

Completed
2.7 years until next milestone

First Posted

Study publicly available on registry

March 20, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

June 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

April 15, 2026

Status Verified

March 1, 2026

Enrollment Period

1 year

First QC Date

July 18, 2023

Last Update Submit

April 10, 2026

Conditions

Thyroid Cancer Stage IVDifferentiated Thyroid CancerAnaplastic Thyroid CancerPoorly Differentiated Thyroid Carcinoma

Keywords

Drug repurposingThyroid cancerNetwork pharmacologyPersonalized therapy

Outcome Measures

Primary Outcomes (2)

  • Feasibility

    Number and proportion of enrolled patients who initiate study treatment.

    12 weeks

  • Safety

    Number and proportion of patients who experience treatment-related adverse events (CTCAE v5.0).

    12 weeks

Secondary Outcomes (1)

  • Preliminary efficacy

    12 weeks

Study Arms (1)

Personalized network-pharmacology-based combination therapy

EXPERIMENTAL

Patients with advanced thyroid cancer undergo tumor molecular profiling using to identify personalized drug repurposing treatments. All drugs are administered at authorized therapeutic doses according to the summary of product characteristics. Treatment regimens vary between patients depending on the identified molecular profile.

Combination Product: Personalised treatment

Interventions

Personalised treatmentCOMBINATION_PRODUCT

The therapy will consist of (one or more) approved drugs.

Personalized network-pharmacology-based combination therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.
  • Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).
  • Measurable disease per RECIST 1.1
  • ECOG performance status ≤ 2
  • Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.

You may not qualify if:

  • Inability to provide informed consent
  • Inability to obtain a (new) biopsy for molecular profiling
  • Pregnancy or breastfeeding.
  • Other active malignancies requiring therapy.
  • Neutropenia (ANC \< 1.5 × 10⁹/L).
  • Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022 Feb;43(2):136-150. doi: 10.1016/j.tips.2021.11.004. Epub 2021 Dec 9.

    PMID: 34895945RESULT

Related Links

MeSH Terms

Conditions

Thyroid NeoplasmsThyroid Carcinoma, Anaplastic

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Study Officials

  • Romana Netea-Maier

    Radboud University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

R Netea-Maier, Prof. Dr.

CONTACT

+31243614599romana.netea-maier@radboudumc.nl

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 18, 2023

First Posted

March 20, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

April 15, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share